Office of Diversion Control, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

May

Myoderm (May 21, 2015)

Mylan Pharmaceuticals, Inc. (May 21, 2015)

Noramco, Inc. (May 21, 2015)

Mallinckrodt, LLC (May 21, 2015)

Fisher Clinical Services, Inc. (May 21, 2015)

PCAS-Nanosyn, LLC (May 21, 2015)

Temporary Placement of Acetyl Fentanyl into Schedule I (May 21, 2015)

The Main Pharmacy; Decision and Order (May 20, 2015)

Keith Ky Ly, D.O.; Decision and Order (May 20, 2015)

Cove Inc., D/B/A Allwell Pharmacy; Decision and Order (May 20, 2015)

Farmacia Yani; Decision and Order (May 20, 2015)

Jana Marjenhoff, D.O.; Decision and Order (May 20, 2015)

Karen S. Dunning, N.P.; Decision and Order (May 19, 2015)

Bobby D. Reynolds, N.P., Tina L. Killebrew, N.P. and David R. Stout, N.P.; Decision and Orders (May 19, 2015)

JM Pharmacy Group, Inc., d/b/a Farmacia Nueva and Best Pharma Corp; Decision and Order (May 19, 2015)

Maryanne Phillips-Elias, M.D.; Decision and Order (May 19, 2015)

Sharad C. Patel, M.D.; Decision and Order (May 19, 2015)

Annicol Marrocco, M.D.; Decision and Order (May 19, 2015)

Cambrex Charles City (May 15, 2015)

Extension of Temporary Placement of UR-144, XLR11, and AKB48 in Schedule I of the Controlled Substances Act (May 15, 2015)

Placement of UR-144, XLR11, and AKB48 Into Schedule I (May 14, 2015)


April

Unither Manufacturing, LLC (April 22, 2015)

Sigma-Aldrich International GMBH, Sigma Aldrich Co., LLC (April 22, 2015)

Pharmacore (April 22, 2015)

Meridian Medical Technologies (April 22, 2015)

Actavis Laboratories FL, Inc. (April 22, 2015)

Rhodes Technologies (April 22, 2015)

Almac Clinical Services Inc. (ACSI) (April 22, 2015)

Johnson Matthey, Inc. (April 22, 2015)

Stepan Company (April 22, 2015)

Siegfried USA, LLC (April 22, 2015)

Cedarburg Pharmaceuticals, Inc. (April 22, 2015)

Actavis Pharma, Inc. (April 22, 2015)

Johnson Matthey Pharmaceutical Materials, Inc. (April 22, 2015)

Pharmacore, Inc. (April 22, 2015)

Stepan Company (April 22, 2015)

Noramco, Inc. (April 22, 2015)

Cambrex Charles City (April 22, 2015)

Sigma Aldrich Research Biochemicals, Inc. (April 22, 2015)

Cayman Chemicals Company (April 22, 2015)

National Center for Natural Products Research (NIDA MProject), Inc. (April 22, 2015)

AMRI Rensselaer, Inc. (April 22, 2015)

Cody Laboratories, Inc. (April 22, 2015)

Proposed Adjustments to the Aggregate Production Quotas for Difenoxin, Diphenoxylate (for conversion), and Marijuana (April 8, 2015)

30-Day Notice (Extension): Reports of Regulated Transactions Involving Extraordinary Quantities, Uncommon Methods of Payment, and Unusual/Excessive Loss or Disappearance, and Regulated Transactions in Tableting/Encapsulating Machines (April 3, 2015)

30-Day Notice (Extension): Application for Registration Renewal, Affidavit for Chain Renewal (DEA Forms 225, 225a and 225b) (April 3, 2015)

30-Day Notice (Extension): Application for Registration and Application for Registration Renewal (DEA Forms 363 and 363a) (April 3, 2015)


March

Hospira (March 27, 2015)

Meda Pharmaceuticals, Inc. (March 27, 2015)

Mylan Pharmaceuticals, Inc. (March 27, 2015)

Apertus Pharmaceuticals (March 27, 2015)

Patheon Pharmaceuticals, Inc. (March 24, 2015)

Penick Corporation (March 24, 2015)

2015 Proposed Aggregate Production Quotas for Three Temporarily Controlled Synthetic Cannabinoids (March 20, 2015)

Substances Temporarily Controlled Under Schedule I of the Controlled Substances Act (March 20, 2015)


February

Johnson Matthey, Inc. (February 19, 2015)

Navinta LLC (February 19, 2015)

Johnson Matthey, Inc. (February 19, 2015)

Mylan Technologies, Inc. (February 19, 2015)

United States Pharmacopeial Convention (February 19, 2015)

Research Triangle Institute (February 19, 2015)

Myoderm (February 11, 2015)

GE Healthcare (February 11, 2015)

Mallinckrodt LLC (February 11, 2015)

Siegfried USA, LLC (February 11, 2015)

Cambridge Isotope Lab (February 11, 2015)

Insys Therapeutics, Inc. (February 11, 2015)

60-Day Notice (Extension): Reports of Regulated Transactions Involving Extraordinary Quantities, Uncommon Methods of Payment, and Unusual/Excessive Loss or Disappearance, and Regulated Transactions in Tableting/Encapsulating Machines (February 6, 2015)

American Radiolabeled Chemicals, Inc. (February 5, 2015)

Chattem Chemicals, Inc. (February 5, 2015)

Cerilliant Corporation (February 5, 2015)


January 2015

Temporary Placement of Three Synthetic Cannabinoids Into Schedule I (January 30, 2015)

60-Day Notice (Extension): Application for Registration Renewal, Affidavit for Chain Renewal (DEA Forms 225, 225a and 225b) (January 30, 2015)

60-Day Notice (Extension): Application for Registration and Application for Registration Renewal (DEA Forms 363 and 363a) (January 30, 2015)

Mallinckrodt LLC (January 28, 2015)

Cambrex Charles City (January 28, 2015)

Research Triangle Institute (January 28, 2015)

Rhodes Technologies (January 28, 2015)

Johnson Matthey, Inc. (January 28, 2015)

Euticals, Inc. (January 26, 2015)

Halo Pharmaceutical, Inc. (January 26, 2015)

Fisher Clinical Services, Inc. (January 26, 2015)

Mylan Pharmaceuticals, Inc. (January 26, 2015)

Noramco, Inc. (January 26, 2015)

Cody Laboratories, Inc. (January 26, 2015)

Catalent CTS, LLC (January 26, 2015)

IRIX Manufacturing, Inc. (January 26, 2015)

Siemens Healthcare Diagnostics, Inc. (January 26, 2015)

Pharmacore, Inc. (January 26, 2015)

Lin Zhi International, Inc. (January 26, 2015)

Euticals, Inc. (January 26, 2015)

Stepan Company (January 26, 2015)

Ampac Fine Chemicals, LLC (January 26, 2015)

Chemtos, LLC (January 26, 2015)

Mallinckrodt, LLC (January 26, 2015)

Chattem Chemicals, Inc. (January 26, 2015)

Wildlife Laboratories, Inc. (January 26, 2015)

Cerilliant Corporation (January 26, 2015)

Apertus Pharmaceuticals (January 26, 2015)

Boehringer Ingelheim Chemical, Inc. (January 26, 2015)

S & B Pharma, Inc. (January 26, 2015)

Research Triangle Institute (January 26, 2015)

Noramco, Inc. (January 26, 2015)

Jose Raul S. Villavicencio, M.D.; Decision and Order (January 23, 2015)

Samuel Mintlow, M.D.; Decision and Order (January 23, 2015)

Removal of Naloxegol From Control (January 23, 2015)

Letter to Registrants: Final Rule Placed Hydrocodone Combinations (HCPs) into Schedule II, effective October 6, 2014 (PDF) (December 2, 2014)

Emergency Disaster Relief
Got Drugs? Turn in your unused or expired medication for safe disposal here.
Alert! Extortion Scam

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Office of Diversion Control  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539